Xencor Stock Jumps After Encouraging Phase 1 Results for XmAb819 in Advanced Kidney Cancer

Xencor selected a Phase 3 dose for XmAb819 after early data showed strong responses in heavily pretreated advanced clear cell kidney cancer patients.